Intensifying Competition and Decline in Tender Projects in China’s Medical Equipment Market
First written in FY2017-Q1. 11 of 24 entries say "Restated". Latest entry: FY2026-H1.
Shimadzu moved to the "Worse" side of this theme in 2018.
0 other companies' latest entry also says "Reframed".
- FY2026-H1ReframedAnnual report
「In China, sales declined because responding to changes in national standards required time, but market conditions are recovering and orders are increasing.」
The factors affecting the Chinese medical equipment market have shifted from the previously cited intensification of competition and delays in bidding to a combination that includes declines caused by delays in responding to changes in national standards, as well as market recovery and increased orders. - FY2025-H1WorsenedAnnual report
「In China, angiography systems increased amid delays in bidding projects due to stronger anti-corruption measures, while X-ray television systems and general radiography systems declined.」
In China's medical equipment market, delays in tenders associated with intensified anti-corruption measures were explicitly identified, with the impact appearing as a decline in X-ray television systems and other products. Revenue in China decreased 32.2% year on year. - FY2024-Q3RestatedAnnual report
「During the nine-month consolidated period ended this third quarter, there were no matters among those concerning the business and financial condition described in this quarterly securities report that occurred and could have a material impact on investors’ decisions, nor were there any material changes to the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company continues to explain that there have been no material changes in business and other risks, including intensified competition in China's medical equipment market. - FY2024-Q2RestatedAnnual report
「During the six months ended the second quarter of the current consolidated fiscal period, there were no occurrences of matters among those concerning the business or accounting situation described in this quarterly report that could materially affect investors' decisions, and no material changes to the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company continues to explain that there have been no material changes in business and other risks, including intensified competition in China's medical equipment market. - FY2023ReframedAnnual report
「In China, although the business was affected by the spread of COVID-19, hospital capital investment increased in the second half of the year due to government supplementary budgets, resulting in growth in mobile X-ray units.」
The description of the Chinese medical equipment business has shifted from focusing on intensified competition with locally produced products and bidding delays to a combination that includes the impact of the spread of infections and a recovery in hospital capital investment driven by supplementary government budgets. - FY2023-Q2ReframedAnnual report
「In China, X-ray TV systems and other products declined due to the effects of localized lockdowns.」
The factors behind the decline in China's medical equipment business include intensified competition from domestic products and delays in bidding, in addition to the impact of localized lockdowns. - FY2022WorsenedAnnual report
「Capital investment stagnated due to intensifying competition with domestically produced products in China and delays in bidding, among other factors.」
In China's medical equipment business, stagnation in capital investment due to intensifying competition and delays in bidding continued throughout the fiscal year, and revenue declined 10.8% from the previous fiscal year. - FY2022-Q3RestatedAnnual report
「In addition to intensifying competition with Chinese manufacturers, capital investment stagnated, including as a result of delayed bidding.」
The disclosure continues to cite intensifying competition with Chinese-capital manufacturers and stagnant capital investment due to delayed tenders in China's medical systems market. - FY2022-Q2WorsenedAnnual report
「Capital investment stagnated due to intensified competition from domestic products and delays in tenders, among other factors.」
In China's Medical Systems business, capital investment stagnated due to intensified competition from domestic products and delays in tenders, while revenue declined 11.4% year on year. - FY2021-Q3RestatedAnnual report
「During the nine-month consolidated period ended this third quarter, there were no matters among those concerning the business and financial condition described in this quarterly securities report that occurred and could have a material impact on investors’ decisions, nor were there any material changes to the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It is stated that there were no significant changes in business and other risks, including intensifying competition in China's medical equipment market. - FY2021-Q2RestatedAnnual report
「During the six months ended the second quarter of the current consolidated fiscal period, there were no occurrences of matters among those concerning the business or accounting situation described in this quarterly report that could materially affect investors' decisions, and no material changes to the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It is stated that there were no significant changes in business and other risks, including intensifying competition in China's medical equipment market. - FY2020WorsenedAnnual report
「In China, although projects for digital mobile examination systems surged in the second half as emergency measures to contain the spread of COVID-19, revenue declined due to intensifying competition and project delays.」
In the Chinese medical equipment business, full-year factors included lower revenue due to intensified competition and project delays, despite an increase in emergency-response projects. - FY2020-Q3RestatedAnnual report
「In China, X-ray imaging systems declined amid intensified competition from domestically produced equipment, in addition to project delays.」
In China's medical equipment business, the decline in X-ray radiography systems due to project delays and intensifying competition from domestically manufactured products has continued. - FY2020-Q2RestatedAnnual report
「In China, X-ray imaging systems declined amid intensified competition from domestically produced equipment, in addition to project delays.」
In China's medical equipment business, the decline in X-ray imaging systems due to delayed projects and intensified competition from domestically produced products was again reported, following the previous quarter. - FY2020-Q1WorsenedAnnual report
「In China, overall sales declined because X-ray imaging systems decreased amid intensifying competition from locally manufactured products, and projects were delayed.」
In the medical equipment business in China, competition with domestically produced products was explicitly described as “intensifying,” and the addition of project delays resulted in an overall decline in revenue. - FY2019-Q3ReframedAnnual report
「In China, overall revenue declined because X-ray imaging systems decreased under policies favoring domestic products, while projects for angiography systems were delayed.」
In China's medical equipment business, the decline in X-ray imaging systems due to preferential policies for domestic products has continued, while the delayed projects have shifted from X-ray TV systems in the previous quarter to angiography systems. - FY2019-Q2WorsenedAnnual report
「In China, overall sales declined as X-ray imaging systems decreased due to the impact of policies favoring domestically produced products, while projects for X-ray TV systems were delayed.」
In addition to continued delays in X-ray TV system projects from the previous quarter, a decline in X-ray radiography systems due to policies favoring domestically manufactured products was identified, making the impact on China's medical equipment business concrete in the form of lower sales. - FY2019-Q1ReframedAnnual report
「In China, demand for general radiography equipment expanded, but overall sales were about the same as the previous year due to delays in X-ray TV system projects.」
In China's medical equipment market, in addition to competition from domestic products, the latest disclosures cite delays in X-ray television system projects that offset growing demand for general radiography equipment, indicating a change in the factors affecting performance. - FY2018-Q2RestatedAnnual report
「During the six months ended the second quarter of the current consolidated fiscal period, there were no occurrences of matters among those concerning the business or accounting situation described in this quarterly report that could materially affect investors' decisions, and no material changes to the “Business and Other Risks” described in the securities report for the previous fiscal year.」
No material changes are described in business and other risks, including intensified competition and fewer bidding projects in China's medical equipment market. - FY2018-Q1WorsenedAnnual report
「In China, sales of multipurpose X-ray TV systems increased, but sales of X-ray radiography systems declined due to competition from domestically produced products, limiting the increase in sales to a marginal level.」
Regarding competition with domestically produced Chinese products, the disclosure now describes the specific impact of lower sales of X-ray imaging systems, rather than merely describing an environment of intensifying competition as in the past. - FY2017RestatedAnnual report
「Although affected by factors including intensifying competition from local companies, sales remained firm in China, supported by strong performance in angiography systems and other products.」
While intensified competition with local Chinese companies continues to be cited as an influencing factor, sales of angiography systems and other products are described as remaining solid. - FY2017-Q3RestatedAnnual report
「During the nine-month consolidated period ended this third quarter, there were no matters among those concerning the business and financial condition described in this quarterly securities report that occurred and could have a material impact on investors’ decisions, nor were there any material changes to the “Business and Other Risks” described in the securities report for the previous fiscal year.」
Although there is no separate restatement regarding intensifying competition and fewer bidding projects in China's medical equipment market, the filing explicitly states that there were no material changes to business and other risks. - FY2017-Q2RestatedAnnual report
「During the six months ended the second quarter of the current consolidated fiscal period, there were no occurrences of matters among those concerning the business or accounting situation described in this quarterly report that could materially affect investors' decisions, and no material changes to the “Business and Other Risks” described in the securities report for the previous fiscal year.」
Although there was no reiteration of declines in individual Chinese competition and bidding projects, it was explicitly stated that there were no significant changes in overall business and other risks. - FY2017-Q1First statedAnnual report
「In China, in addition to intensifying competition with local manufacturers in general radiography systems, tender projects temporarily declined,」
Competition and fewer tender projects in China were cited as affecting sales in the medical equipment business.